期刊
DIABETES RESEARCH AND CLINICAL PRACTICE
卷 104, 期 3, 页码 297-322出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.diabres.2014.02.014
关键词
Type 2 diabetes; Glucose reabsorption; SGLT2 inhibitors; Dapagliflozin; Canagliflozin; Empagliflozin
The kidney plays an important role in glucose homeostasis via its production, utilization, and, most importantly, reabsorption of glucose from glomerular filtrate which is largely mediated via the sodium glucose co-transporter 2 (SGLT2). Pharmacological inhibition of SGLT2 increases urinary glucose excretion and decreases plasma glucose levels in an insulin-independent manner. Agents that inhibit SGLT2 represent a novel class of drugs, which has recently become available for treatment of type 2 diabetes. This article summarizes the rationale for use of these agents and reviews available clinical data on their efficacy, safety, and risks/benefits. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据